TD Cowen raised the firm’s price target on Vera Therapeutics (VERA) to $73 from $60 and keeps a Buy rating on the shares. The firm raised its target to basedon higher peak US sales of $1.64B in 2033.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Optimistic Buy Rating for Vera Therapeutics Amid Strategic Advancements and Financial Projections
- Vera Therapeutics price target raised to $99 from $52 at JPMorgan
- Strategic Positioning and Market Opportunities Favor Vera Therapeutics: A Buy Recommendation
- Vera Therapeutics rises 19.2%
- These 3 Stocks Have Triple-Digit Upside Potential, Say Five-Star Analysts – 11/26/2025